Literature DB >> 3922796

Recombinant gamma-interferon inhibits prostaglandin-mediated and parathyroid hormone-induced bone resorption in cultured neonatal mouse calvaria.

M Peterlik, O Hoffmann, P Swetly, K Klaushofer, K Koller.   

Abstract

A role of gamma-interferon in the bone remodeling process can be implicated from its interference with bone resorptive processes in cultured neonatal mouse calvaria. The immune interferon is an efficient inhibitor of endogenous prostaglandin synthesis, particularly after stimulation by thrombin or arachidonic acid, and, in addition, has a calcitonin-like inhibitory effect on PTH-induced osteoclastic bone resorption.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3922796     DOI： 10.1016/0014-5793(85)80924-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  5 in total

Review 1.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

2.  Cyclosporines: correlation of immunosuppressive activity and inhibition of bone resorption.

Authors:  P J Stewart; P H Stern
Journal:  Calcif Tissue Int       Date:  1989-10       Impact factor: 4.333

3.  Prolonged and ubiquitous inhibition by interferon gamma of bone resorption induced by parathyroid hormone-related protein, 1,25-dihydroxyvitamin D3, and interleukin 1 in fetal mouse forearm bones.

Authors:  Y Fujii; K Sato; K Kasono; T Satoh; T Fujii; K Shizume
Journal:  Calcif Tissue Int       Date:  1990-09       Impact factor: 4.333

4.  Inhibitory effects of gamma-interferon on bradykinin-induced bone resorption and prostaglandin formation in cultured mouse calvarial bones.

Authors:  U H Lerner; O Ljunggren; M Ransjö; K Klaushofer; M Peterlik
Journal:  Agents Actions       Date:  1991-03

5.  Comparative study of inhibitory effects by murine interferon gamma and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK).

Authors:  M Tohkin; S Kakudo; H Kasai; H Arita
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.